for you activities. business full on and TRACON’s fourth conference our an update call. I pipeline thank year and quarter financial recent XXXX afternoon joining Good with and results update and will begin
for will that, three our of President year-ended our XX, months the Following results December Finance, Scott and review financial Brown Vice XXXX.
Finally, we taking your questions. will conclude by
begin U.S., now lead patients for subject angiosarcoma a is to enrolled Kingdom. Poland. and United has interim trial Let’s continues of with required trigger TRCXXX, the preparations enrolling the brief is at update France, enroll Austria, more TAPPAS our currently well trial X and that asset the The on than a XX the to patient Phase randomized XXXth in which sites analysis.
to the in the to of a lie a will DMC futility. terminate the the If unfavorable total size favorable patients be expect the the In results enroll zone. will the zone, elect patients also interim enrichment cutaneous be patients. needed will early meet sample total trial and We the the XXX total In disease. the promising size a interim that trial of for with and be a lie could XXX zone, the to The in zone with total of XXX size sample DMC trial scenario, will final of of gets trial April. provide in the complete in the patients results sample XXX the
or Symposia of combination enroll ASCO. liver that that Phase of or RECIST. X XX% Nexavar partial TRCXXX of seventeen Cancers Three confirmed had updated by response, reported also continue in patients such the data patient evaluable XX of patients multi-center Gastrointestinal We evaluable responses in partial RECIST to responses four cancer a by developed additional partial time, to-date. and with trial Since have one demonstrated XX% has
the In TRAXAR by For single in reported X%. trials, cancer X comparison, in December, liver separate partial treated Phase our and with or compared was when we patients RECIST and with single that response not metastatic Inlyta TRCXXX improving agent Inlyta. trial survival X% X Phase free of confirmed agent Nexavar patients meet cancer rate advanced did endpoint primary in kidney the progression of to
the combination well-tolerated was that of to We Leiden and this tumor cancer. we models. consistent year. preclinical were combination updated AACR showing toxicity TRCXXX who checkpoint patient conclude six to in each a at Phase In Opdivo preclinical in are with in of combination American part with are Association for patients These In conference interest from cell June, as in this present TRCXXX data investigators later in Opdivo lung currently reported dose trial Annual the synergistic patients with data at X inhibitor TRCXXX trial without a activity at Philadelphia we a study Meeting of therapy this of on non-small and December, March. dosing the Cancer of and work, appropriately presented Research or development will Based present this escalation. the dose-limiting treated expect from investigators working the in data University best manner with researchers of scientific
checkpoint Opdivo prior one patients, top-line and progressed currently a data cohorts, expansion one progressed report reacquired partial in China stable And tumors these inhibitor not prior are response trial treatment Patients following TRCXXX one includes of following to not six patients in treatment on February, other remains PD-LXand prior One had yet for expect inhibitor express disease. enrolling of received rights whose XXXX. of more we received whom than from from the into study patient months. two cohorts remain developed Ambrx. on with did twelve not treatment. checkpoint who parallel who Two checkpoint treatment, archival Greater we prior XX to develop patients inhibitor and these includes have patients have late who In five
recall will upfront. that to for we that You $X for December XXXX, million rights in licensed terms a Ambrx TRCXXX commercial included
us X that Following engage trial clinical including discussions towards a China, Ambrx China reverting now now initiating their to to liver to in in elected us. lead efforts agreement, Greater progress TRCXXX our regarding terminate rights cancer. development include business all for identifying corporate TRCXXX substantial TRCXXX a more the resulting partner or to Europe with clinical China license We they Phase with Japan. Ambrx parallel, had to in of an emphasis in in capabilities partners one in development and TRCXXX expect notified new development, In
that expects X reminder, the of the be basis retained a Phase the U.S. in As could rights data trial and if to for initial commercial approval TRACON TAPPAS U.S. TRCXXX TRCXXX the commercialization positive, and subsequent its
the Turning ophthalmic formulation of now TRCXXX. DE-XXX to
with Santen, the accruing substantial U.S. with amendment retained like rights opportunity that with VEGF to expected to to an vision meaningfully regulatory Phase experience and in Lucentis remaining improved high-single-digits milestones DE-XXX global there not in in study X do following potential with $XXX low-teen patients treatment and in three including developed million was first doses or provide trial combination and DE-XXX the of with AMD compares AVANTE inhibitors. greater trial different partner commercialization majority wet the size power royalty sites TRACON patients single-agent wet at VEGF the continues XX patients agents randomized on of that XXXX, ten be following developmental data will combined dose with endoglin angiogenetic sales. treatment to single-agent with significant in of financial the inhibitors AMD to as see arm for net developmental, wet the effect. believe Our pathways a the potential patients of for patients to essential target a treatment We which is Lucentis are two half increase in now The AMD. sample treatment
We did TRCXXX of responses trial of the the of patients. tolerable, Annual at Meeting. will product base novel meet in the to Temodar certain DNA rights and turn efficacy is small to XX In repair TRCXXX, XXXX, the endpoint is we with for not was Phase candidate, now reverse molecule TRACON’s TRCXXX demonstrating X The resistance enrolled Temodar recurrent Neuro-Oncology glioblastoma patients a November pathway, objective in which top-line intended but from chemotherapeutics. second initial primary excision combination the inhibitor that retained Society of data reported to and
survival TRCXXX patients models. benefit free more endpoint months other of met months. demonstrated survival clinical of In However, demonstrated XX% glycosylase, the or evidence who six conducted expressed two and secondary being a by XX in progression trial Institute. associated our is free beyond and Cancer patients than preclinical with in biomarker activity of for Both National Temodar TRCXXX progression the
present will of from in cancer colorectal Annual expanded an with AACR Meeting at cohort patients April. We the data
a a to In The addition, Case TRCXXX Phase there Western of Phase California with X/X consisting and Western continues combination of patients of X of a are Consortia and Phase and Consortia And three patients mesothelioma trial lung Cancer Phase in Alimta with radiation patients the arm other ongoing dosing University. with Cancer cancer of in with a cohort TRCXXX X X in dual TRCXXX Case enroll continues TRCXXX cohort therapy. in by being cisplatin with Alimtain California trials trial for performed chemotherapy tumors. solid
validated data likely whether represent showing preclinical the program samples believe in these to patient are to treatments. As being glycosylase of validation tumor part associated most is significant determine assessed TRCXXX studies, respond sensitivity could a of We be with to patients the identifying advancement biomarker for clinic. tumor by TRCXXX expression
to on X/X TRCXXX, cancer our that a studying are treating we in prostate Moving candidate trial. for Phase
first data to conference present Phase Phase of therapy a have receptor enrolling of and circulating expect allow at testing in now the XX androgen are the X patients patients approximately progressed the the in incorporate portion half treatments. XXXX tumor we prostate biomarker cancer the who We sites trial of X trial, X scientific at Phase In the inhibitor the of following directed DNA portion to for U.S. in
in transaction royalty data their following $XX granted TRCXXX Phase with kinase also a opt potential advance that to to Janssen to study top-line rights receive myeloma. exercise of milestones low-single-digit independently. X inhibitor if molecule right not asset payment the from treatment Janssen is novel TRCXXX, can proof-of-concept data, NF-kappa-B-inducing and a is does potent TRACON TRCXXX on hematologic intended small sales. including a XXXX XXXX, X million for patients The they We As malignancies, this and Phase up of reported TRACON If the we licensed reacquire Janssen in entitled in expect from upfront million XXXX. TRACON $XXX.X in,
Janssen. did of not determined Following preclinical and returned of we rights development warrant development compound further to have completion TRCXXX, the all
strong maintain Janssen We additional with a continue discussing working future. to forward opportunities the them product with to in development potentially and relationship look
business clinical innovative autoimmune company of On and Chinese-based the biologics stage Biopharma, biopharmaceutical on front, executed two immune-oncology the with in I-Mab a November, significant partnerships development diseases. development we focused in
from dosing second clinical the Phase sharing territories begin bispecific to TJXXXX, TJXXXX phased The TRACON a and for payments and first TRACON up asset bispecific first I-Mab. development in potential. the North strategic royalty TRACON payments in-license if for in commercialization. weeks to the agreement a of trials collaboration clinical I-Mab’s product collaboration the of each third-party. regulatory receive TJXXXX executing cost of the TRACON a proprietary IND with a trial develop cost early submitted I-Mab license portions development the TRACON and advanced I-Mab of whereby also X bearing TCXXXX right best-in-class escalating for developments. that and more IND half for patients receive I-Mab opting the will America I-Mab of of and development proprietary XXXX. TRACON the leading the Notably with and allows can TRACON certain escalate novel responsible was five and be cleared phase In non-royalty in cost-sharing January, CDXX of cost into I-Mab’s entered and development to to December expect with A antibody FDA provides outlicense may rights the antibodies on TRACON we in clinical has and they of stages in antibodies develop within four cancer depending agreement which to of TJXXXX an with
become the development and deals U.S. cost, the risk we believe clinical model. As evidenced companies a to by select preferred in for share solution I-Mab, TRACON with recent can profit commercialization a and
two XXXX, trial develop capital product our Phase benefit accessing expected development the TRCXXX data are U.S. in from as lung Our and drug well of currently to X assets the our resources first-in-class perspective, randomized trial data has trial X this cancer, expanded from efforts will AVANTE additional includes and rapid and Santen's X Phase we fund who data capital-efficient or companies the capacity solution. to will interim platform which late to turn assets readouts. XXX, OPDIVO first this TJXXXX. an TAPPAS our TRC as financials. product which U.S. continue from TRACON and identify top-line be at of Scott, a and results call cohort update X we believe operations At platform on who from From our our with over provide offers planned clinical-stage I into analysis ex from The time, to a clinical-stage study, expected development Phase Phase time from to the development quarter financial best-in-class sufficient
